Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049556 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients With Cervical Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00049556: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00049556 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049556, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of cervical cancer. Comparing results of diagnostic procedures performed before, during, and after treatment with gefitinib may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with cervical cancer.
Interventions
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- DRUG gefitinib
- PROCEDURE sentinel lymph node biopsy
- OTHER surface-enhanced laser desorption/ionization-time of flight mass spectrometry
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00049556 record still lists
NCT00049556 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which biopsy is the first listed.
NCT00049556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00049556 about?
NCT00049556 is a clinical study titled "Gefitinib in Treating Patients With Cervical Cancer". RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of cervical cancer. Comparing results of diagnostic procedures performed before, during, and after treatment with gefitinib may help doctors predict a patient's response to treatmen...
What is the current status of trial NCT00049556?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-10. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00049556?
The interventions under investigation include: biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), gefitinib (DRUG), sentinel lymph node biopsy (PROCEDURE), surface-enhanced laser desorption/ionization-time of flight mass spectrometry (OTHER).
Who is sponsoring clinical trial NCT00049556?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia